SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma spurts on reporting 20% rise in Q3 consolidated net profit

02 Feb 2016 Evaluate

Ajanta Pharma is currently trading at Rs 1306.00, up by 2.95 points or 0.23% from its previous closing of Rs 1303.05 on the BSE.

The scrip opened at Rs 1305.00 and has touched a high and low of Rs 1319.45 and Rs 1282.10 respectively. So far 32723 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1720.00 on 12-Aug-2015 and a 52 week low of Rs. 968.86 on 05-Feb-2015.

Last one week high and low of the scrip stood at Rs. 1319.45 and Rs. 1212.00 respectively. The current market cap of the company is Rs. 11484.16 crore.

The promoters holding in the company stood at 73.78% while Institutions and Non-Institutions held 10.76% and 15.46% respectively.

Ajanta Pharma has reported 21.99% rise in its net profit at Rs 103.34 crore for the quarter ended December 31, 2015 as compared to Rs 84.71 crore for the same quarter in the previous year. The company’s total income has increased by 15.02% to Rs 424.23 crore for the quarter under review from Rs 368.84 crore for the corresponding quarter of the previous year.  

On the consolidated basis, the company has reported 19.60% rise in its net profit after taxes, minority interest and share of profit / (loss) of associates of Rs 111.30 crore for the quarter ended December 31, 2015 as compared to Rs 93.06 crore for the same quarter in the previous year. Total income of the company has increased by 15.03% at Rs 474.38 crore for quarter under review as compared to Rs 412.39 crore for the quarter ended December 31, 2014.      

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×